Provided by Tiger Trade Technology Pte. Ltd.

Akebia Therapeutics

0.9539
-0.0761-7.39%
Volume:4.88M
Turnover:4.77M
Market Cap:264.33M
PE:-8.58
High:1.05
Open:1.03
Low:0.9500
Close:1.03
52wk High:3.20
52wk Low:0.8140
Shares:277.11M
Float Shares:269.24M
Volume Ratio:0.55
T/O Rate:1.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1112
EPS(LYR):-0.0208
ROE:-109.38%
ROA:-1.05%
PB:10.57
PE(LYR):-45.90

Loading ...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 03

Akebia Therapeutics Price Target Maintained with a $6.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 01

Analysts Are Bullish on These Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Akebia Therapeutics (AKBA)

TIPRANKS
·
Jul 01

Akebia Therapeutics, US Renal Care Halt Kidney Disease Trial After Positive Interim Analysis

MT Newswires Live
·
Jun 30

Akebia Therapeutics - Usrc Kidney Research Stops Voice Trial After Interim Analysis Shows Improved Safety with Vafseo

THOMSON REUTERS
·
Jun 30

Akebia Therapeutics - Voice Trial Meets Stopping Criteria with Win Odds of 1.16 as of June 1, 2026

THOMSON REUTERS
·
Jun 30

Akebia Therapeutics - no Significant Difference in Mortality: Vafseo 8.77% vs Esa 8.78% Per 100 Patient-years

THOMSON REUTERS
·
Jun 30

Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch

Simply Wall St.
·
Jun 24

Akebia Therapeutics shareholders approved authorized share increase amendment at annual meeting

Reuters
·
Jun 23

Akebia Therapeutics Secures New Patent Covering Dosing Regimen for Chronic Kidney Disease

MT Newswires Live
·
Jun 10

Akebia says new Vafseo dosing patent is listed in FDA Orange Book

Reuters
·
Jun 10

Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

GlobeNewswire
·
Jun 10

Akebia Therapeutics grants new hire options for 8,400 shares at $1.02 each

Reuters
·
Jun 02

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 02

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

GlobeNewswire
·
May 28

Akebia Therapeutics Earnings Call: Vafseo Drives Transition

TIPRANKS
·
May 20

Akebia Therapeutics Balances Vafseo Momentum With Headwinds

TIPRANKS
·
May 09

Akebia Q1 revenue falls, net income misses analyst estimates on higher expenses

Reuters
·
May 07

Akebia Q1 FY26 turns to net loss of $9.1 million; revenue falls to $53.5 million

Reuters
·
May 07

Akebia Therapeutics Q1 EPS $(0.03), Inline, Sales $53.544M Beat $51.668M Estimate

Benzinga Earnings
·
May 07